NASDAQ:GWPH - GW Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$218.96
+0.30 (1.20%)
Get New GW Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GWPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GWPH

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for GW Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a -100.00% upside from the last price of $218.96.

This chart shows the closing price for GWPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in GW Pharmaceuticals. This rating has held steady since February 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 8 hold ratings
  • 0 sell ratings
11/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 10 hold ratings
  • 0 sell ratings
2/26/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 10 hold ratings
  • 0 sell ratings
5/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 0 sell ratings
8/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 8 hold ratings
  • 0 sell ratings
11/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/21/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/22/2021Raymond JamesReiterated RatingNeutral ➝ HoldLow
2/4/2021CitigroupDowngradeBuy ➝ NeutralLow
2/4/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$200.00 ➝ $220.00Medium
2/4/2021Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$193.00 ➝ $220.00Medium
2/4/2021HC WainwrightDowngradeBuy ➝ Neutral$162.00 ➝ $220.00Medium
2/3/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$193.00 ➝ $220.00Low
2/3/2021Cantor FitzgeraldDowngradeOverweight ➝ NeutralMedium
2/3/2021Northland SecuritiesDowngradeOutperform ➝ Market PerformLow
2/3/2021Needham & Company LLCReiterated RatingBuy ➝ HoldHigh
12/29/2020Cantor FitzgeraldLower Price TargetOverweight$165.00 ➝ $147.00N/A
11/4/2020HC WainwrightReiterated RatingBuyLow
8/24/2020Raymond JamesInitiated CoverageMarket PerformHigh
8/10/2020GuggenheimLower Price TargetBuy$160.00 ➝ $155.00Medium
8/7/2020The Goldman Sachs GroupSet Price TargetBuy ➝ In-Line$171.00 ➝ $271.00High
8/7/2020Bank of AmericaReiterated RatingBuy$234.00High
8/7/2020Needham & Company LLCLower Price TargetBuy$190.00 ➝ $180.00High
8/4/2020HC WainwrightBoost Price TargetBuy$161.00 ➝ $164.00Medium
8/3/2020OppenheimerReiterated RatingBuy$166.00 ➝ $183.00Medium
8/3/2020Cantor FitzgeraldBoost Price TargetOverweight$160.00 ➝ $165.00Low
7/14/2020Stifel NicolausDowngradeBuy ➝ Hold$150.00 ➝ $140.00High
6/30/2020Evercore ISIBoost Price TargetOutperform$250.00 ➝ $275.00Low
5/29/2020OppenheimerInitiated CoverageBuy$173.00 ➝ $166.00Low
5/14/2020Cantor FitzgeraldBoost Price TargetOverweight$120.00 ➝ $154.00High
5/12/2020Needham & Company LLCReiterated RatingBuy$190.00Medium
4/8/2020Northland SecuritiesInitiated CoverageOutperform$128.00High
3/5/2020CitigroupInitiated CoverageBuy$192.00Medium
2/27/2020HC WainwrightLower Price TargetBuy$170.00 ➝ $161.00High
2/26/2020Cantor FitzgeraldReiterated RatingBuy$174.00High
2/26/2020Bank of AmericaLower Price TargetBuy$233.00 ➝ $227.00High
2/26/2020OppenheimerLower Price TargetOutperform$203.00 ➝ $173.00Low
2/26/2020Needham & Company LLCLower Price TargetBuy$200.00 ➝ $190.00High
2/7/2020Evercore ISIInitiated CoverageBuy$260.00Medium
1/2/2020JPMorgan Chase & Co.Initiated CoverageOverweight$134.00Low
12/18/2019HC WainwrightReiterated RatingBuy$170.00Low
11/11/2019Evercore ISIReiterated RatingBuyMedium
11/8/2019HC WainwrightReiterated RatingBuyLow
11/6/2019Cantor FitzgeraldReiterated RatingOverweight$174.00 ➝ $174.00Low
11/6/2019OppenheimerLower Price TargetOutperform$222.00Low
10/30/2019HC WainwrightInitiated CoverageBuy$170.00Low
10/21/2019Needham & Company LLCInitiated CoverageBuy$200.00Medium
9/27/2019OppenheimerLower Price TargetOutperform$239.00 ➝ $233.00Low
9/25/2019Bank of AmericaReiterated RatingBuy$218.00Medium
8/7/2019Morgan StanleyBoost Price TargetOverweight$238.00Low
8/7/2019OppenheimerBoost Price TargetBuy$234.00 ➝ $239.00Low
7/26/2019CowenReiterated RatingBuy$200.00Medium
5/8/2019OppenheimerDowngradeOutperform ➝ Market Perform$195.00Low
5/8/2019JPMorgan Chase & Co.UpgradeMarket Perform ➝ OutperformLow
5/7/2019GuggenheimReiterated RatingBuy ➝ Buy$186.00 ➝ $222.00Low
5/7/2019CIBCUpgradeMarket Perform ➝ OutperformHigh
5/7/2019Piper Jaffray CompaniesBoost Price TargetOverweight$185.00 ➝ $210.00High
5/7/2019JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$180.00 ➝ $215.00High
5/7/2019Cantor FitzgeraldReiterated RatingPositive ➝ Overweight$196.00 ➝ $229.00High
5/7/2019OppenheimerUpgradeMarket Perform ➝ Outperform$162.00 ➝ $234.00High
4/29/2019OppenheimerBoost Price Target$142.00 ➝ $162.00Low
4/9/2019Morgan StanleyReiterated RatingBuyLow
3/18/2019Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$193.00 ➝ $196.00Low
2/27/2019Cantor FitzgeraldReiterated RatingBuy$193.00High
2/27/2019Piper Jaffray CompaniesReiterated RatingOverweight$185.00High
2/22/2019GuggenheimInitiated CoverageBuy$178.00High
1/7/2019AltaCorp CapitalReiterated RatingOutperformMedium
1/2/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$134.00High
12/11/2018OppenheimerInitiated CoverageHold$142.00 ➝ $142.00Low
12/9/2018Cantor FitzgeraldLower Price Target$211.00 ➝ $193.00Low
12/4/2018Cantor FitzgeraldReiterated RatingOverweightLow
12/3/2018Cantor FitzgeraldLower Price TargetOverweight ➝ Buy$211.00 ➝ $193.00Medium
11/27/2018Cantor FitzgeraldSet Price TargetBuy$211.00Medium
11/12/2018SVB LeerinkInitiated CoverageOutperform$185.00Low
11/5/2018Piper Jaffray CompaniesReiterated RatingOverweight ➝ OverweightLow
10/11/2018Morgan StanleySet Price TargetBuy$240.00 ➝ $227.00High
9/28/2018Bank of AmericaReiterated RatingBuy ➝ Buy$181.00 ➝ $197.00Medium
9/28/2018Morgan StanleyBoost Price TargetOverweight$197.00 ➝ $240.00High
9/27/2018Cantor FitzgeraldSet Price TargetBuy$211.00Low
9/7/2018Morgan StanleySet Price TargetOverweight ➝ Overweight$197.00Medium
8/14/2018Stifel NicolausInitiated CoverageBuy$181.00Medium
8/8/2018Cantor FitzgeraldLower Price TargetOverweight$235.00 ➝ $211.00High
7/12/2018Cantor FitzgeraldSet Price TargetBuy$235.00Low
6/26/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$170.00 ➝ $200.00High
5/9/2018CowenReiterated RatingBuy$165.00Low
4/19/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$192.00 ➝ $205.00High
4/17/2018Cantor FitzgeraldSet Price TargetBuy$192.00Medium
2/21/2018Cantor FitzgeraldSet Price TargetBuy$192.00High
2/6/2018Bank of AmericaLower Price TargetBuy ➝ Buy$154.00 ➝ $149.00High
2/6/2018SVB LeerinkBoost Price TargetOutperform ➝ Outperform$153.00 ➝ $157.00High
2/5/2018Cantor FitzgeraldReiterated RatingBuy ➝ Buy$208.00 ➝ $192.00Medium
1/23/2018SVB LeerinkReiterated RatingBuy$153.00Medium
12/14/2017The Goldman Sachs GroupUpgradeNeutral ➝ Buy$174.00Medium
12/4/2017Cantor FitzgeraldSet Price TargetBuy$208.00High
11/20/2017Cantor FitzgeraldReiterated RatingBuy$208.00N/A
11/14/2017Bank of AmericaLower Price TargetBuy$160.00 ➝ $158.00N/A
10/6/2017The Goldman Sachs GroupReiterated RatingNeutral ➝ Neutral$124.00N/A
10/2/2017Cantor FitzgeraldReiterated RatingOverweight$208.00Medium
10/2/2017CowenReiterated RatingOutperform$165.00Medium
10/2/2017SVB LeerinkReiterated RatingOutperform$160.00 ➝ $153.00Medium
8/16/2017Evercore ISIInitiated CoverageOutperform ➝ Outperform$154.00Medium
8/10/2017SVB LeerinkReiterated RatingOutperform$162.00 ➝ $160.00Medium
8/8/2017Cantor FitzgeraldSet Price TargetBuy$208.00High
8/8/2017Maxim GroupDowngradeBuy ➝ Hold$61.00High
8/7/2017Maxim GroupSet Price TargetBuy$135.00Low
6/8/2017Maxim GroupSet Price TargetBuy$135.00High
5/25/2017Maxim GroupReiterated RatingBuy$135.00Low
(Data available from 5/22/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/24/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/23/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/22/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
3/23/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
GW Pharmaceuticals logo
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.
Read More

Today's Range

Now: $218.96
Low: $218.96
High: $218.96

50 Day Range

MA: $218.59
Low: $216.90
High: $219.28

52 Week Range

Now: $218.96
Low: $87.07
High: $219.57

Volume

N/A

Average Volume

899,771 shs

Market Capitalization

$6.86 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.15

Frequently Asked Questions

What sell-side analysts currently cover shares of GW Pharmaceuticals?

The following Wall Street research analysts have issued reports on GW Pharmaceuticals in the last year:
View the latest analyst ratings for GWPH.

What is the current price target for GW Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for GW Pharmaceuticals in the last year.
View the latest price targets for GWPH.

What is the current consensus analyst rating for GW Pharmaceuticals?

GW Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for GWPH.

How do I contact GW Pharmaceuticals' investor relations team?

GW Pharmaceuticals' physical mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company's listed phone number is 44-12-2326-6800 and its investor relations email address is [email protected] The official website for GW Pharmaceuticals is www.gwpharm.com. Learn More about contacing GW Pharmaceuticals investor relations.